Comparison of Visfatin Levels in Patients with Breast Cancer and Endometrial Cancer with Healthy Individuals: A Systematic Review and Meta-analysis

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2022 Nov 23

PMID 36415563

Authors

Hori Ghaneialvar

Samira Shiri

Azra Kenarkoohi

Zahra Fallah Vastani

Alireza Ahmadi

Ali Khorshidi

Roghayeh Khooz

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Endometrial cancer (EC) and breast cancer (BC) are prevalent in women. Visfatin is an adipokine that, in addition to being involved in metabolism and inflammation, may also be interested in carcinogenesis. Visfatin measurement in cancer patients has shown that visfatin levels in cancer patients differed from those in healthy subjects. Various studies have shown that the level of visfatin is increased in people within EC and BC, and this difference has a significant relationship with prognosis.

Methods: A comprehensive search of related articles from PubMed, Scopus, Web of Science, and the Google Scholar database was done by November 2021. Eligible articles measured visfatin levels in patients with breast cancer and EC. After selecting the eligible studies, the data were extracted and analyzed using the random effect method.

Results: Given the effect size and the confidence interval obtained, the total level of visfatin in cancer patients was different from that in healthy individuals, and this difference was statistically significant. However, the difference in visfatin levels in patients with breast cancer was much more significant than in patients with EC compared to the control group.

Conclusions: Due to the significant increase in visfatin levels in these patients, visfatin may be a potential prognostic factor in breast and ECs. Visfatin levels in cancer patients differed from those in healthy subjects, and this difference was also statistically significant (-values = 0.00). Visfatin levels also differed between breast cancer patients and healthy individuals, which was statistically significant (-values = 0.00). The difference in visfatin levels between patients with EC and healthy subjects was statistically significant (-values = 0.047).

Citing Articles

Breast cancer shares many epidemiological, lifestyle, and local hormonal and metabolic underpinnings with endometrial and ovarian cancer: a narrative review.

Rodriguez Y, Koomson A, Perry R Transl Breast Cancer Res. 2025; 6:8.

PMID: 39980815 PMC: 11836739. DOI: 10.21037/tbcr-24-39.

Exploring the multifaceted role of obesity in breast cancer progression.

Kakkat S, Suman P, Turbat-Herrera E, Singh S, Chakroborty D, Sarkar C Front Cell Dev Biol. 2024; 12():1408844.

PMID: 39040042 PMC: 11260727. DOI: 10.3389/fcell.2024.1408844.

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer.

Travelli C, Colombo G, Aliotta M, Fagiani F, Fava N, De Sanctis R J Immunother Cancer. 2023; 11(10).

PMID: 37880182 PMC: 10603332. DOI: 10.1136/jitc-2023-007010.

The Role of Selected Adipocytokines in Ovarian Cancer and Endometrial Cancer.

Stepien S, Olczyk P, Gola J, Komosinska-Vassev K, Mielczarek-Palacz A Cells. 2023; 12(8).

PMID: 37190027 PMC: 10136739. DOI: 10.3390/cells12081118.

Updated Clinical Evidence on the Role of Adipokines and Breast Cancer: A Review.

Verras G, Tchabashvili L, Chlorogiannis D, Mulita F, Argentou M Cancers (Basel). 2023; 15(5).

PMID: 36900364 PMC: 10000674. DOI: 10.3390/cancers15051572.

References

Braun M, Overbeek-Wager E, Grumbo R . Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016; 93(6):468-74. View

Mohammadi M, Mianabadi F, Mehrad-Majd H . Circulating visfatin levels and cancers risk: A systematic review and meta-analysis. J Cell Physiol. 2018; 234(4):5011-5022. DOI: 10.1002/jcp.27302. View

Wang Z, Gao S, Sun C, Li J, Gao W, Yu L . Clinical significance of serum adiponectin and visfatin levels in endometrial cancer. Int J Gynaecol Obstet. 2019; 145(1):34-39. DOI: 10.1002/ijgo.12772. View

Mohammadi M, Moradi A, Farhadi J, Akbari A, Pourmandi S, Mehrad-Majd H . Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis. Cytokine. 2020; 127:154964. DOI: 10.1016/j.cyto.2019.154964. View

Ilhan T, Kebapcilar A, Yilmaz S, Ilhan T, Secilmis Kerimoglu O, Pekin A . Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis. Asian Pac J Cancer Prev. 2015; 16(11):4503-8. DOI: 10.7314/apjcp.2015.16.11.4503. View

Moi S, Lee Y, Chuang L, Yuan S, Ou-Yang F, Hou M . Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression. Cancer Cell Int. 2018; 18:19. PMC: 5807850. DOI: 10.1186/s12935-018-0517-z. View

Patel S, Mistry T, Brown J, Digby J, Adya R, Desai K . A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides. 2009; 31(1):51-7. DOI: 10.1016/j.peptides.2009.10.001. View

Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G . Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol Oncol. 2013; 129(3):505-12. DOI: 10.1016/j.ygyno.2013.02.022. View

Faria S, Devine C, Rao B, Sagebiel T, Bhosale P . Imaging and Staging of Endometrial Cancer. Semin Ultrasound CT MR. 2019; 40(4):287-294. DOI: 10.1053/j.sult.2019.04.001. View

10.

Hung A, Lo S, Hou M, Lee Y, Tsai C, Chen Y . Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation. Clin Cancer Res. 2016; 22(17):4478-90. DOI: 10.1158/1078-0432.CCR-15-2704. View

11.

Nergiz Avcioglu S, Altinkaya S, Kucuk M, Yuksel H, Kurt Omurlu I, Yanik S . Visfatin concentrations in patients with endometrial cancer. Gynecol Endocrinol. 2014; 31(3):202-7. DOI: 10.3109/09513590.2014.975687. View

12.

Wang Y, Chen H, Lo S, Chen Y, Huang Y, Hu S . Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages. Cancers (Basel). 2020; 12(12). PMC: 7760195. DOI: 10.3390/cancers12123526. View

13.

Dalamaga M . Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Med Hypotheses. 2012; 79(5):617-21. DOI: 10.1016/j.mehy.2012.07.036. View

14.

Vona-Davis L, Rose D . Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14(2):189-206. DOI: 10.1677/ERC-06-0068. View

15.

Zhu Y, Guo M, Zhang L, Xu T, Wang L, Xu G . Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer. Oncol Rep. 2015; 35(1):454-62. DOI: 10.3892/or.2015.4391. View

16.

Shackelford R, Mayhall K, Maxwell N, Kandil E, Coppola D . Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer. 2014; 4(11-12):447-56. PMC: 3877665. DOI: 10.1177/1947601913507576. View

17.

Assiri A, Kamel H, Hassanien M . Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers. 2015; 2015:253519. PMC: 4369904. DOI: 10.1155/2015/253519. View

18.

Luhn P, Dallal C, Weiss J, Black A, Huang W, Lacey Jr J . Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2013; 22(7):1304-12. PMC: 3819202. DOI: 10.1158/1055-9965.EPI-13-0258. View

19.

Sun Y, Zhao Z, Yang Z, Xu F, Lu H, Zhu Z . Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017; 13(11):1387-1397. PMC: 5715522. DOI: 10.7150/ijbs.21635. View

20.

Sun Y, Zhu S, Wu Z, Huang Y, Liu C, Tang S . Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma. Oncotarget. 2017; 8(14):23427-23435. PMC: 5410315. DOI: 10.18632/oncotarget.15080. View